1 / 4

Cisplatin monotherapy pCR in 34/50 (68%) !!! PR in 15/50 (30%) SD in 1/50 (2%)

Breast cancers with BRCA1 Treatment – neoa djuvant therapy. Cisplatin monotherapy pCR in 34/50 (68%) !!! PR in 15/50 (30%) SD in 1/50 (2%) 10/60 pts on treatment. Breast cancers with BRCA1 Treatment – neoa djuvant therapy. 50 pts 7 - second primary BC treated CHTH

piera
Download Presentation

Cisplatin monotherapy pCR in 34/50 (68%) !!! PR in 15/50 (30%) SD in 1/50 (2%)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breast cancers with BRCA1 Treatment – neoadjuvant therapy • Cisplatin monotherapy • pCRin 34/50(68%) !!! • PR in 15/50(30%) • SD in 1/50 (2%) • 10/60 pts on treatment

  2. Breast cancers with BRCA1 Treatment – neoadjuvant therapy 50 pts 7 - second primary BC treated CHTH in the past 4 - treated CHTH before CISPL SURGERY + CHTH (CMF, AT, FAC, AC) 8 pts – PR 3 pts - pCR

  3. Breast cancers with BRCA1 Treatment – neoadjuvant therapy 39 pts 31/39 = 79,5% pCR CISPLATIN – first option of CHTH!

  4. Breast cancers with BRCA1 Cis-platinum neoadjuvant therapy (first treatment) for sub-groups of tumors T3-4 or T2 N(+) • CPR - 77.3% (17 / 22)

More Related